|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
ATE352612T1
(de)
|
1990-08-29 |
2007-02-15 |
Pharming Intellectual Pty Bv |
Homologe rekombination in säugetier-zellen
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
US6130364A
(en)
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
AU708239B2
(en)
|
1995-06-29 |
1999-07-29 |
Immunex Corporation |
Cytokine that induces apoptosis
|
|
CA2277757C
(en)
|
1997-01-15 |
2008-09-16 |
Phoenix Pharmacologics, Inc. |
Modified tumor necrosis factor
|
|
US6342363B1
(en)
|
1997-01-28 |
2002-01-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 nucleic acids and methods
|
|
US6072047A
(en)
|
1997-02-13 |
2000-06-06 |
Immunex Corporation |
Receptor that binds trail
|
|
CA2294704A1
(en)
|
1997-06-26 |
1999-01-07 |
Immunex Corporation |
Protein that binds trail
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6329148B1
(en)
|
1999-02-16 |
2001-12-11 |
The Board Of Trustees Of The Leland Stanford University |
Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7550143B2
(en)
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
CA2363712C
(en)
|
1999-05-17 |
2011-05-10 |
Conjuchem Inc. |
Long lasting insulinotropic peptides
|
|
US7160924B2
(en)
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
WO2001022987A1
(en)
|
1999-09-30 |
2001-04-05 |
The Trustees Of The University Of Pennsylvania |
Trail: an inhibitor of autoimmune inflammation and cell cycle progression
|
|
IL136156A0
(en)
|
2000-05-16 |
2001-05-20 |
Compugen Ltd |
Sequences of trail variants
|
|
US20040005314A1
(en)
|
2001-07-27 |
2004-01-08 |
Enrique Escandon |
Apo-2l receptor agonist and cpt-11 synergism
|
|
KR100396983B1
(ko)
|
2000-07-29 |
2003-09-02 |
이강춘 |
고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
|
|
CA2422076A1
(en)
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceutical Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
|
KR20020056565A
(ko)
|
2000-12-29 |
2002-07-10 |
황규언 |
인간유래 세포 소멸 인자와 그 수용체의 결합체인ＴＲＡＩＬ-ｓＤＲ5 결합체의 결정화에 의한 3차원 구조및 ＴＲＡＩＬ 결실 돌연변이 단백질
|
|
US20020169123A1
(en)
|
2001-02-27 |
2002-11-14 |
The Trustees Of The University Of Pennsylvania |
Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
|
|
US7615233B2
(en)
|
2001-07-10 |
2009-11-10 |
Canon Kabushiki Kaisha |
Particulate construct comprising polyhydroxyalkanoate and method for producing it
|
|
DE10144252A1
(de)
|
2001-08-31 |
2003-03-27 |
Fraunhofer Ges Forschung |
Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
|
|
IL161051A0
(en)
|
2001-10-02 |
2004-08-31 |
Genentech Inc |
Apo-2 ligand variants and uses thereof
|
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
|
JP2006501820A
(ja)
|
2002-09-06 |
2006-01-19 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
|
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
EP1558631A4
(en)
|
2002-10-30 |
2006-10-04 |
Pfizer Prod Inc |
METHOD AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER IN PETS
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
AU2004238794A1
(en)
|
2003-05-09 |
2004-11-25 |
Genentech, Inc. |
Apo2L (trail) receptor binding peptides and uses thereof
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
US7795404B1
(en)
|
2003-08-08 |
2010-09-14 |
Five Prime Therapeutics, Inc. |
Human soluble notch receptor ligands
|
|
GB0328261D0
(en)
|
2003-12-05 |
2004-01-07 |
Univ Groningen |
Improved cytokine design
|
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
WO2006009731A1
(en)
|
2004-06-18 |
2006-01-26 |
Genentech, Inc. |
Methods of using apo2l receptor agonists and nk cell activators
|
|
WO2006010057A2
(en)
|
2004-07-08 |
2006-01-26 |
Amgen Inc. |
Therapeutic peptides
|
|
US20060046961A1
(en)
*
|
2004-09-02 |
2006-03-02 |
Mckay William F |
Controlled and directed local delivery of anti-inflammatory compositions
|
|
BRPI0515615A
(pt)
*
|
2004-09-08 |
2008-07-29 |
Genentech Inc |
métodos para tratar células cancerosas e doença imune relacionada
|
|
WO2006042848A2
(en)
|
2004-10-18 |
2006-04-27 |
Novo Nordisk A/S |
Growth hormone conjugates
|
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
US20060188498A1
(en)
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
EP1695717A1
(en)
|
2005-02-23 |
2006-08-30 |
Ludwig-Maximilians-Universität |
Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
|
|
US20060228352A1
(en)
|
2005-02-24 |
2006-10-12 |
Schoenberger Stephen P |
TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
|
|
EP1874824A4
(en)
|
2005-04-06 |
2009-12-30 |
Ibc Pharmaceuticals Inc |
METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
|
|
AU2006232310B9
(en)
|
2005-04-06 |
2011-07-21 |
Ibc Pharmaceuticals, Inc. |
Improved stably tethered structures of defined compositions with multiple functions or binding specificities
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
EP1745802A1
(en)
|
2005-07-20 |
2007-01-24 |
Kreatech Biotechnology B.V. |
Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
|
|
CA2607056C
(en)
|
2005-10-19 |
2015-11-24 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
GB0524316D0
(en)
|
2005-11-29 |
2006-01-04 |
Medical Res Council |
Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
|
|
JP5096363B2
(ja)
|
2005-12-16 |
2012-12-12 |
ネクター セラピューティックス |
Ｇｌｐ−１のポリマ複合体
|
|
CA2636424A1
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
|
|
KR100784485B1
(ko)
|
2006-01-18 |
2007-12-11 |
한국과학기술연구원 |
생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
|
|
WO2007102690A1
(en)
|
2006-03-06 |
2007-09-13 |
Postech Foundation |
Vector including the codon-optimized dna cassette for producing secretory recombinant dodecamer trail
|
|
KR100746962B1
(ko)
|
2006-04-04 |
2007-08-07 |
한국과학기술연구원 |
온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도
|
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
|
CN101074261A
(zh)
*
|
2006-04-30 |
2007-11-21 |
北京同为时代生物技术有限公司 |
Trail受体1和/或trail受体2特异性抗体及其应用
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
KR100886783B1
(ko)
|
2006-06-12 |
2009-03-04 |
성균관대학교산학협력단 |
N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
|
|
NZ574009A
(en)
|
2006-06-20 |
2012-01-12 |
Genentech Inc |
Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components
|
|
CA2656379A1
(en)
|
2006-06-21 |
2007-12-27 |
Apogenix Gmbh |
Differential cytokine expression in human cancer
|
|
WO2008088582A2
(en)
|
2006-08-04 |
2008-07-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials related to trail isoforms
|
|
EP2059606A4
(en)
|
2006-09-06 |
2010-04-07 |
Phasebio Pharmaceuticals Inc |
PEPTIDE FUSION THERAPEUTIC COMPOSITIONS
|
|
WO2009126558A1
(en)
|
2008-04-10 |
2009-10-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
|
|
WO2008120832A1
(en)
|
2007-03-30 |
2008-10-09 |
Industry-Academic Cooperation Foundation, Yonsei University |
Human neural stem cell secreting a smac, preparation method and use thereof
|
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
KR100968591B1
(ko)
|
2007-06-14 |
2010-07-08 |
한국과학기술연구원 |
약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
|
|
WO2009014744A1
(en)
|
2007-07-25 |
2009-01-29 |
Alexion Pharmaceutical, Inc. |
Methods and compositions for treating autoimmune disease
|
|
WO2009020094A1
(ja)
|
2007-08-09 |
2009-02-12 |
Daiichi Sankyo Company, Limited |
疎水性分子で修飾した抗体
|
|
EP2214716B1
(en)
|
2007-10-23 |
2021-11-17 |
Nektar Therapeutics |
Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
|
|
EP2215246B1
(en)
|
2007-10-31 |
2015-01-07 |
MedImmune, LLC |
Protein scaffolds
|
|
GB0723059D0
(en)
|
2007-11-23 |
2008-01-02 |
Nat Univ Ireland |
Improved cytokine design
|
|
US20090203671A1
(en)
|
2007-11-27 |
2009-08-13 |
Abbott Laboratories |
Method of treating cancer
|
|
GB0724532D0
(en)
|
2007-12-17 |
2008-01-30 |
Nat Univ Ireland |
Trail variants for treating cancer
|
|
CL2009001191A1
(es)
|
2008-05-14 |
2010-07-02 |
Genentech Inc |
Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
|
|
US20100068302A1
(en)
|
2008-09-17 |
2010-03-18 |
Traslational Cancer Drugs Pharma, S.L. |
Methods and compositions for the treatment of cancer
|
|
US20120021995A1
(en)
|
2008-10-10 |
2012-01-26 |
Anaphore, Inc. |
Polypeptides that Bind TRAIL-R1 and TRAIL-R2
|
|
GB0818649D0
(en)
|
2008-10-10 |
2008-11-19 |
Nat Univ Ireland |
Treatment of proliferative disorders with trail
|
|
CA2739663A1
(en)
|
2008-10-10 |
2010-05-15 |
Anaphore, Inc. |
Polypeptides that bind trail-r1 and trail-r2
|
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
|
EP3912643B8
(en)
|
2009-02-13 |
2023-08-23 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
IN2012DN01331A
(https=)
|
2009-08-31 |
2015-06-05 |
Ibc Pharmaceuticals Inc |
|
|
WO2011079293A1
(en)
|
2009-12-23 |
2011-06-30 |
Ambrx, Inc |
Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
|
|
WO2011080314A2
(en)
|
2009-12-31 |
2011-07-07 |
Deutsches Krebsforschungszentrum |
Novel modulators of trail signalling
|
|
WO2011106707A2
(en)
|
2010-02-26 |
2011-09-01 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to dr3
|
|
CA2795325A1
(en)
|
2010-04-13 |
2011-10-20 |
Medimmune, Llc |
Fibronectin type iii domain-based multimeric scaffolds
|
|
US8461311B2
(en)
|
2010-06-08 |
2013-06-11 |
Washington University |
TRAIL trimers, methods and uses therefor
|
|
KR101209266B1
(ko)
|
2010-06-30 |
2012-12-06 |
한국과학기술연구원 |
생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
|
|
NZ610153A
(en)
|
2010-10-29 |
2014-07-25 |
Daiichi Sankyo Co Ltd |
Novel anti-dr5 antibody
|
|
EP2468764A1
(en)
|
2010-12-24 |
2012-06-27 |
Rijksuniversiteit te Groningen |
TNF family ligand variants
|
|
EP2670426B1
(en)
|
2011-01-31 |
2017-05-10 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
|
US20140105898A1
(en)
|
2011-02-28 |
2014-04-17 |
Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo |
Apoptosis-inducing molecules and uses therefor
|
|
US20140079722A1
(en)
|
2011-03-09 |
2014-03-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
JP6130307B2
(ja)
|
2011-03-17 |
2017-05-17 |
ザ ユニバーシティ オブ バーミンガム |
再指向性免疫療法
|
|
US20130101553A1
(en)
|
2011-04-18 |
2013-04-25 |
The Regents Of The University Of California |
Inducing inactivation of fibrogenic myofibroblasts
|
|
FI4335511T3
(fi)
|
2011-04-29 |
2026-01-29 |
Penn State Res Found |
Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona
|
|
US20140178398A1
(en)
|
2011-05-03 |
2014-06-26 |
Genentech, Inc |
Vascular disruption agents and uses thereof
|
|
FI20115640A0
(fi)
|
2011-06-22 |
2011-06-22 |
Turun Yliopisto |
Yhdistelmähoito
|
|
US8586020B2
(en)
|
2011-06-30 |
2013-11-19 |
Korea Institute Of Science And Technology |
Poly(organophosphazene) composition for biomaterials
|
|
ES2582869T3
(es)
|
2011-07-05 |
2016-09-15 |
Bioasis Technologies Inc |
Conjugados de P97-anticuerpo
|
|
CN111592601A
(zh)
|
2011-07-06 |
2020-08-28 |
江苏靶标生物医药研究所有限公司 |
一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
|
|
CN102898526A
(zh)
|
2011-07-28 |
2013-01-30 |
山东先声麦得津生物制药有限公司 |
一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
EP2831116A1
(en)
|
2012-03-28 |
2015-02-04 |
Amgen Inc. |
Dr5 receptor agonist combinations
|
|
WO2013156054A1
(en)
|
2012-04-16 |
2013-10-24 |
Universität Stuttgart |
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
|
|
EP2877572B1
(en)
|
2012-07-24 |
2018-11-28 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
|
US20150038511A1
(en)
|
2012-08-09 |
2015-02-05 |
Celgene Corporation |
Treatment of immune-related and inflammatory diseases
|
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
|
CN104755936B
(zh)
|
2012-08-30 |
2018-04-27 |
图尔库大学 |
选择个性化脑癌疗法的方法
|
|
EP3345923A1
(en)
|
2012-09-20 |
2018-07-11 |
MorphoSys AG |
Treatment for rheumatoid arthritis with anti-gm-csf antibody
|
|
US20140134647A1
(en)
|
2012-11-01 |
2014-05-15 |
La Jolla Institute For Allergy And Immunology |
Novel crystal structure and ligand binding sites of trail receptor
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
EP2922861A4
(en)
|
2012-11-26 |
2016-09-14 |
Caris Life Sciences Switzerland Holdings Gmbh |
BIOMARKER COMPOSITIONS AND METHODS
|
|
US9873747B2
(en)
*
|
2013-01-31 |
2018-01-23 |
Thomas Jefferson University |
Fusion proteins that facilitate cancer cell destruction
|
|
EP2956185B1
(en)
|
2013-02-13 |
2021-12-29 |
Agency For Science, Technology And Research |
A polymeric system for release of an active agent
|
|
WO2015010615A1
(zh)
|
2013-07-23 |
2015-01-29 |
四川大学华西医院 |
一种重组trail蛋白及其制备方法和用途
|
|
CN115124573A
(zh)
|
2013-09-02 |
2022-09-30 |
杭州多禧生物科技有限公司 |
应用于细胞结合分子-药物共轭体的新型细胞毒性分子
|
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
|
PL222795B1
(pl)
|
2013-12-22 |
2016-09-30 |
Univ Warszawski |
Rekombinowane białko fuzyjne ProSTAT do zastosowania w leczeniu
|
|
CA2938919C
(en)
|
2014-02-28 |
2020-12-29 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
|
US11299528B2
(en)
|
2014-03-11 |
2022-04-12 |
D&D Pharmatech Inc. |
Long acting TRAIL receptor agonists for treatment of autoimmune diseases
|
|
DK3145530T3
(da)
*
|
2014-04-21 |
2021-06-14 |
D&D Pharmatech Inc |
Trail receptor agonists for treatment of fibrotic diseases
|
|
US9901620B2
(en)
*
|
2014-04-21 |
2018-02-27 |
Theraly Pharmaceuticals, Inc. |
Trail receptor agonists for treatment of fibrotic disease
|
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|